$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000142072023000009 Filed on February 14, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2021 Q4
Revenue	$0.00	$0.00	$168.0K
YoY Change	-100.0%	-100.0%	-76.17%
Cost Of Revenue			$113.0K
YoY Change			-46.45%
Gross Profit			$55.00K
YoY Change			-88.87%
Gross Profit Margin			32.74%
Selling, General & Admin	$3.525M	$7.229M	$8.362M
YoY Change	-58.66%	-13.55%	44.02%
% of Gross Profit			15203.64%
Research & Development	$2.644M	$2.779M	$3.331M
YoY Change	-52.37%	-16.57%	40.31%
% of Gross Profit			6056.36%
Depreciation & Amortization	$193.0K	$241.0K	$517.0K
YoY Change	-72.78%	-53.38%	353.51%
% of Gross Profit			940.0%
Operating Expenses	$6.169M	$10.57M	$11.69M
YoY Change	-56.18%	-9.58%	45.45%
Operating Profit	-$6.169M	-$10.57M	-$11.64M
YoY Change	-49.36%	-9.15%	54.25%
Interest Expense	$35.00K	$31.00K	$328.0K
YoY Change	-86.0%	-90.55%	-46.67%
% of Operating Profit
Other Income/Expense, Net	-$110.0K	$10.00K	-$282.0K
YoY Change	-47.12%	-103.55%	-51.88%
Pretax Income	-$6.279M	-$10.56M	-$11.92M
YoY Change	-49.32%	-11.38%	46.6%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.294M	-$33.55M	-$11.92M
YoY Change	-41.13%	181.48%	46.64%
Net Earnings / Revenue			-7095.24%
Basic Earnings Per Share	-$0.55	-$3.42	-$1.37
Diluted Earnings Per Share	-$0.55	-$3.42	-$54.68K
COMMON SHARES
Basic Shares Outstanding	12.37M	9.007M	218.0M
Diluted Shares Outstanding	13.18M	9.807M	8.715M

Balance Sheet

Concept	2023 Q1	2022 Q4	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.562M	$9.625M	$57.38M
YoY Change	-86.49%	-83.22%	-46.7%
Cash & Equivalents	$6.562M	$3.696M	$39.21M
Short-Term Investments	$0.00	$5.929M	$18.17M
Other Short-Term Assets	$19.29M	$20.87M	$2.922M
YoY Change	721.16%	614.27%	51.24%
Inventory			$1.986M
Prepaid Expenses
Receivables	$70.00K	$970.0K	$111.0K
Other Receivables	$1.172M	$6.769M	$5.100M
Total Short-Term Assets	$27.09M	$38.24M	$67.50M
YoY Change	-55.08%	-43.35%	-39.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.358M	$4.245M	$32.88M
YoY Change	-87.4%	-87.09%	556.31%
Goodwill
YoY Change
Intangibles	$5.393M	$5.398M	$5.041M
YoY Change	9.64%	7.08%	325.4%
Long-Term Investments			$1.760M
YoY Change
Other Assets	$3.303M	$303.0K	$7.176M
YoY Change	-52.44%	-95.78%	29800.0%
Total Long-Term Assets	$17.29M	$13.57M	$58.95M
YoY Change	-68.59%	-76.99%	70.76%
TOTAL ASSETS
Total Short-Term Assets	$27.09M	$38.24M	$67.50M
Total Long-Term Assets	$17.29M	$13.57M	$58.95M
Total Assets	$44.39M	$51.80M	$126.4M
YoY Change	-61.53%	-59.03%	-13.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.013M	$4.002M	$2.739M
YoY Change	-61.87%	46.11%	13.7%
Accrued Expenses	$3.821M	$5.001M	$2.842M
YoY Change	30.01%	75.97%	68.87%
Deferred Revenue
YoY Change
Short-Term Debt	$13.70M	$16.01M	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$421.0K	$411.0K	$45.00K
YoY Change	835.56%	813.33%	-85.58%
Total Short-Term Liabilities	$22.28M	$27.78M	$8.346M
YoY Change	169.0%	232.79%	36.77%
LONG-TERM LIABILITIES
Long-Term Debt	$1.496M	$1.878M	$22.10M
YoY Change	-93.25%	-91.5%	-30.89%
Other Long-Term Liabilities	$3.225M	$3.324M	$5.400M
YoY Change	-41.87%	-38.44%
Total Long-Term Liabilities	$4.721M	$5.202M	$27.50M
YoY Change	-82.96%	-81.09%	-14.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.28M	$27.78M	$8.346M
Total Long-Term Liabilities	$4.721M	$5.202M	$27.50M
Total Liabilities	$27.00M	$32.98M	$35.85M
YoY Change	-24.99%	-8.01%	-5.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$282.9M	-$275.6M	-$194.5M
YoY Change	36.75%	41.71%
Common Stock	$300.3M	$294.6M	$285.2M
YoY Change	4.83%	3.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.39M	$18.82M	$90.60M
YoY Change
Total Liabilities & Shareholders Equity	$44.39M	$51.80M	$126.4M
YoY Change	-61.53%	-59.03%	-13.04%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2021 Q4
OPERATING ACTIVITIES
Net Income	-$7.294M	-$33.55M	-$11.92M
YoY Change	-41.13%	181.48%	46.64%
Depreciation, Depletion And Amortization	$193.0K	$241.0K	$517.0K
YoY Change	-72.78%	-53.38%	353.51%
Cash From Operating Activities	-$3.872M	-$7.635M	-$10.69M
YoY Change	-34.86%	-28.55%	26.93%
INVESTING ACTIVITIES
Capital Expenditures	-$201.0K	$2.954M	-$2.133M
YoY Change	-90.32%	-238.49%	111.82%
Acquisitions
YoY Change
Other Investing Activities	$8.040M	$1.699M	$1.161M
YoY Change	209.95%	46.34%	-109.72%
Cash From Investing Activities	$8.241M	-$1.255M	-$972.0K
YoY Change	1494.0%	29.12%	-92.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.464M	-3.044M	-6.017M
YoY Change	-14740.0%	-49.41%	-117.15%
NET CHANGE
Cash From Operating Activities	-3.872M	-7.635M	-10.69M
Cash From Investing Activities	8.241M	-1.255M	-972.0K
Cash From Financing Activities	1.464M	-3.044M	-6.017M
Net Change In Cash	5.833M	-11.93M	-17.68M
YoY Change	-207.28%	-32.48%	-228.93%
FREE CASH FLOW
Cash From Operating Activities	-$3.872M	-$7.635M	-$10.69M
Capital Expenditures	-$201.0K	$2.954M	-$2.133M
Free Cash Flow	-$3.671M	-$10.59M	-$8.553M
YoY Change	-5.07%	23.8%	15.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12368287
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.08
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.83
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.94
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.43
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-2.34
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.54
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-3.60
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.97
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.42
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.40
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9807000
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8715000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9324000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8715000
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9807000
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8715000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9324000
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8715000
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.08
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.83
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.94
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-2.34
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.54
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-3.60
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.97
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.42
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.54
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35023
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.40
	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.43
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bryan
	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
	us-gaap	Lease Practical Expedients Package LeasePracticalExpedientsPackage	false
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8727158
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77807
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2797813
	dei	City Area Code CityAreaCode	979
	dei	Local Phone Number LocalPhoneNumber	446-0027
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Entity Address Address Line1 EntityAddressAddressLine1	8800 HSC Parkway
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Trading Symbol TradingSymbol	IBIO
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22676000
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12369154
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3696000
CY2022Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	5929000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2022Q4	us-gaap	Liabilities Liabilities	32977000
CY2022Q2	us-gaap	Liabilities Liabilities	35921000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	970000
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000000
CY2022Q4	us-gaap	Settlement Assets Current SettlementAssetsCurrent	5100000
CY2022Q2	us-gaap	Settlement Assets Current SettlementAssetsCurrent	5100000
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1669000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	414000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1549000
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	20457000
CY2022Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	3900000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	38235000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	45070000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	253000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5996000
CY2022Q2	ibio	Convertible Promissory Note Receivable And Accrued Interest ConvertiblePromissoryNoteReceivableAndAccruedInterest	1631000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	746000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2873000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3068000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4245000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1373000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5398000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4851000
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	50000
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	29000
CY2022Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	74000
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	37314000
CY2022Q4	us-gaap	Assets Assets	51800000
CY2022Q2	us-gaap	Assets Assets	99406000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4002000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4264000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5001000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3764000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	259000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	315000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	91000
CY2022Q4	ibio	Equipment Financing Payable Current EquipmentFinancingPayableCurrent	152000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	16011000
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	22161000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	88000
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000
CY2022Q4	ibio	Current Liabilities Related To Assets Held For Sale CurrentLiabilitiesRelatedToAssetsHeldForSale	1947000
CY2022Q2	ibio	Current Liabilities Related To Assets Held For Sale CurrentLiabilitiesRelatedToAssetsHeldForSale	56000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27775000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	30436000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	490000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3324000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3514000
CY2022Q4	ibio	Equipment Financing Payable Noncurrent EquipmentFinancingPayableNoncurrent	323000
CY2022Q4	ibio	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	1065000
CY2022Q2	ibio	Noncurrent Liabilities Related To Assets Held For Sale NoncurrentLiabilitiesRelatedToAssetsHeldForSale	1971000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12368287
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8727158
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	12000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	9000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	294591000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	287619000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-167000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-213000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275613000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223930000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	18823000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	63485000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51800000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	99406000
CY2022Q4	us-gaap	Revenues Revenues	0
CY2021Q4	us-gaap	Revenues Revenues	0
	us-gaap	Revenues Revenues	84000
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2779000
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1859000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5327000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2993000
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7794000
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5372000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12882000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9547000
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	10573000
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	7231000
	us-gaap	Operating Expenses OperatingExpenses	18209000
	us-gaap	Operating Expenses OperatingExpenses	12540000
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-10573000
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-7231000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18209000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12456000
CY2022Q4	us-gaap	Interest Expense InterestExpense	31000
CY2021Q4	us-gaap	Interest Expense InterestExpense	0
	us-gaap	Interest Expense InterestExpense	31000
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	41000
CY2021Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	140000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	71000
CY2022Q4	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	0
CY2021Q4	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	5000
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	5000
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10000
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	40000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	109000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	76000
CY2022Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10563000
CY2021Q4	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7191000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-18100000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-12380000
CY2022Q4	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	0
CY2021Q4	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	0
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-1000
CY2022Q4	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	0
CY2022Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10563000
CY2021Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7191000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-18100000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-12379000
CY2021Q4	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	22000
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	88000
CY2022Q4	ibio	Net Loss Available To Stockholders From Continuing Operations NetLossAvailableToStockholdersFromContinuingOperations	-10563000
CY2021Q4	ibio	Net Loss Available To Stockholders From Continuing Operations NetLossAvailableToStockholdersFromContinuingOperations	-7213000
	ibio	Net Loss Available To Stockholders From Continuing Operations NetLossAvailableToStockholdersFromContinuingOperations	-18100000
	ibio	Net Loss Available To Stockholders From Continuing Operations NetLossAvailableToStockholdersFromContinuingOperations	-12467000
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-22990000
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-4729000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-33583000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-8480000
CY2022Q4	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-33553000
CY2021Q4	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-11942000
	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-51683000
	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-20947000
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-33553000
CY2021Q4	us-gaap	Profit Loss ProfitLoss	-11920000
	us-gaap	Profit Loss ProfitLoss	-51683000
	us-gaap	Profit Loss ProfitLoss	-20860000
CY2022Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	56000
CY2021Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-27000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	46000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-28000
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-33497000
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11947000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-51637000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-20888000
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.08
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.83
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.94
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.43
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.34
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.54
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-3.60
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.97
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.42
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.40
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9807000
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8715000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9324000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8715000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63485000
CY2022Q3	ibio	Stock Issued During Period Value Capital Raise StockIssuedDuringPeriodValueCapitalRaise	1151000
CY2022Q3	ibio	Common Stock Issued In Rubryc Transaction Value CommonStockIssuedInRubrycTransactionValue	650000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1222000
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-10000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-18130000
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48368000
CY2022Q4	ibio	Stock Issued During Period Value Capital Raise StockIssuedDuringPeriodValueCapitalRaise	3500000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	56000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-33553000
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	636000
CY2022Q4	ibio	Fractional Share Issued After Reverse Stock Split Value FractionalShareIssuedAfterReverseStockSplitValue	-39000
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1127000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18823000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	108568000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	821000
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-1000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-8940000
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	100525000
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	967000
CY2021Q4	ibio	Adjustments To Additional Paid In Capital Acquisition Of Remaining Portion Of Affiliate AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate	50000
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1103000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-27000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-11920000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	90598000
	us-gaap	Profit Loss ProfitLoss	-51683000
	us-gaap	Profit Loss ProfitLoss	-20860000
	us-gaap	Share Based Compensation ShareBasedCompensation	2349000
	us-gaap	Share Based Compensation ShareBasedCompensation	1924000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	211000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	88000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	563000
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	201000
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	246000
	us-gaap	Depreciation Depreciation	388000
	us-gaap	Depreciation Depreciation	823000
	ibio	Accrued Interest Receivable On Convertible Promissory Note Receivable AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable	38000
	ibio	Accrued Interest Receivable On Convertible Promissory Note Receivable AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable	38000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	62000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	195000
	ibio	Deferred Financing Costs Amortization Expense DeferredFinancingCostsAmortizationExpense	123000
	ibio	Deferred Financing Costs Amortization Expense DeferredFinancingCostsAmortizationExpense	0
	ibio	Increase Decrease In Inventory Reserve IncreaseDecreaseInInventoryReserve	4933000
	ibio	Increase Decrease In Inventory Reserve IncreaseDecreaseInInventoryReserve	0
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	17649000
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	565000
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	5000
	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	0
	ibio	Forgiveness Of Note Payable And Accrued Interest Sba Loan ForgivenessOfNotePayableAndAccruedInterestSbaLoan	607000
	ibio	Settlement Of Revenue Contract SettlementOfRevenueContract	84000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-31000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3000
	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	1058000
	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	1959000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1134000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	971000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-74000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	811000
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-21000
	ibio	Capital Expenditure Incurred For Intangible Assets Paid CapitalExpenditureIncurredForIntangibleAssetsPaid	791000
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-17000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1178000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	872000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1237000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	522000
	ibio	Increase Decrease In Accrued Liabilities Noncurrent IncreaseDecreaseInAccruedLiabilitiesNoncurrent	1065000
	ibio	Increase Decrease In Accrued Liabilities Noncurrent IncreaseDecreaseInAccruedLiabilitiesNoncurrent	0
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	30000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-11000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-34000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21594000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20033000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	4336000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4899000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5511000
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	1173000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2867000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5433000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3256000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	692000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1226000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6121000
	ibio	Proceeds From Issuance Of Preferred And Common Stock ProceedsFromIssuanceOfPreferredAndCommonStock	4015000
	ibio	Proceeds From Issuance Of Preferred And Common Stock ProceedsFromIssuanceOfPreferredAndCommonStock	0
	ibio	Payments For Fractional Shares After Reverse Stock Split PaymentsForFractionalSharesAfterReverseStockSplit	39000
	ibio	Payments For Fractional Shares After Reverse Stock Split PaymentsForFractionalSharesAfterReverseStockSplit	0
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	50000
	ibio	Proceeds From Equipment Financing Loan ProceedsFromEquipmentFinancingLoan	500000
	ibio	Proceeds From Equipment Financing Loan ProceedsFromEquipmentFinancingLoan	0
	ibio	Payment Of Equipment Financing Loan PaymentOfEquipmentFinancingLoan	25000
	ibio	Payment Of Equipment Financing Loan PaymentOfEquipmentFinancingLoan	0
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6250000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	77000
	ibio	Payments To Attain Term Note PaymentsToAttainTermNote	22000
	ibio	Payments To Attain Term Note PaymentsToAttainTermNote	322000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	82000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5810000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1903000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6105000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24723000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32259000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28672000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77404000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3949000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45145000
	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	329000
	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	404000
	ibio	Capital Expenditure Incurred For Intangible Assets Paid CapitalExpenditureIncurredForIntangibleAssetsPaid	1769000
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	814000
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
	ibio	Increase Decrease In Finance Lease Obligations For New Leases IncreaseDecreaseInFinanceLeaseObligationsForNewLeases	814000
	ibio	Increase Decrease In Finance Lease Obligations For New Leases IncreaseDecreaseInFinanceLeaseObligationsForNewLeases	0
	ibio	Common Stock Issued In Rubryc Transaction Value CommonStockIssuedInRubrycTransactionValue	650000
	ibio	Common Stock Issued In Rubryc Transaction Value CommonStockIssuedInRubrycTransactionValue	0
	ibio	Cost To Raise Capital Paid Directly From Gross Proceeds CostToRaiseCapitalPaidDirectlyFromGrossProceeds	636000
	ibio	Cost To Raise Capital Paid Directly From Gross Proceeds CostToRaiseCapitalPaidDirectlyFromGrossProceeds	0
	ibio	Termination Of Finance Lease Right Of Use Asset Including Issuance Of Warrant TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant	0
	ibio	Termination Of Finance Lease Right Of Use Asset Including Issuance Of Warrant TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant	25386000
	us-gaap	Notes Issued1 NotesIssued1	0
	us-gaap	Notes Issued1 NotesIssued1	22375000
	ibio	Non Cash Transaction Increase In Right Of Use Assets And Liabilities NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities	0
	ibio	Non Cash Transaction Increase In Right Of Use Assets And Liabilities NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities	5570000
	ibio	Stock Purchase Agreement Value Of Shares To Be Purchased StockPurchaseAgreementValueOfSharesToBePurchased	0
	ibio	Stock Purchase Agreement Value Of Shares To Be Purchased StockPurchaseAgreementValueOfSharesToBePurchased	2500000
	ibio	Non Cash Settlement Of Revenue Contract NonCashSettlementOfRevenueContract	0
	ibio	Non Cash Settlement Of Revenue Contract NonCashSettlementOfRevenueContract	580000
	ibio	Warrants Issued For Finance Lease Payment WarrantsIssuedForFinanceLeasePayment	0
	ibio	Warrants Issued For Finance Lease Payment WarrantsIssuedForFinanceLeasePayment	217000
	ibio	Lease Incentive For Construction In Progress LeaseIncentiveForConstructionInProgress	0
	ibio	Lease Incentive For Construction In Progress LeaseIncentiveForConstructionInProgress	82000
	ibio	Noncash Or Part Noncash Acquisition Non Controlling Interest Assumed NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed	0
	ibio	Noncash Or Part Noncash Acquisition Non Controlling Interest Assumed NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed	18000
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	46000
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	28000
	us-gaap	Interest Paid Net InterestPaidNet	363000
	us-gaap	Interest Paid Net InterestPaidNet	612000
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1. Nature of Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio, Inc. (“we”, “us”, “our”, “iBio”, “iBio, Inc” or the “Company”) is an Artificial Intelligence (“AI”)-driven innovator of precision antibody immunotherapies. The Company has a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where we may face reduced competition and with antibodies that may be more selective. The Company plans to use its AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><img alt="Graphic" src="ibio-20221231x10q001.jpg" style="display:inline-block;height:219.9pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:540pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IBIO-101: </b>an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (“Tregs”) via antibody-dependent cellular cytotoxicity (“ADCC”), without disrupting activation of effector T-cells (“Teffs”) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer. IBIO-101 is currently in the Investigational New Drug (“IND”) enabling stage. We have contracted with a contract research organization (CRO) to assist with the development of the manufacturing process, which includes but not limited to process and cell line development for the production of the drug substance and drug product. As we continue with the development of the manufacturing process for IBIO-101, as a fast-follower to a competing drug candidate, we have decided to pause the IND enabling studies until our competitor releases clinical data. Due to the decision to pause the IND enabling studies, we expect the IND filing for IBIO-101 will be delayed from the first half of 2024 to the first half of 2025. This delay will allow us to thoroughly evaluate the market potential and optimize our financial resources and the development plan for IBIO-101 to maximize its potential for success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">EGFRvIII: </b>binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. EGFRvIII is constantly “switched on” which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CCR8:</b> targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">MUC16:</b> a highly expressed target on ovarian cancer cells and an attractive tumor associated target for therapeutic antibodies. However, antibodies targeting MUC16 are prone to tumor resistance via epitope shedding and dysregulated glycosylation. Epitope-steered antibodies that bind to an epitope that avoids both of these tumor resistance mechanisms could potentially be used to treat MUC16 positive tumors, particularly those tumors that are resistant to other MUC16 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PD-1 Agonist: </b>selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the programs described above, the Company also has five additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IBIO-100 and Endostatin E4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our preclinical anti-fibrotic program, IBIO-100, has been undergoing a review process as part of our ongoing effort to prioritize our resources and focus on the most promising opportunities. The IBIO-100 program design is based in part upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. After careful consideration, we have decided to terminate all efforts on IBIO-100 anti-fibrotic program and to cancel the license agreement with the University of Pittsburgh. The lead optimization and manufacturing of IBIO-100 have proven to be very challenging, and we will continue to prioritize our resources to fit into our immune-oncology monoclonal antibody strategy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of this decision, we are intending to complete the pre-clinical cancer studies we are conducting in collaboration with University of Texas Southwestern using E4 endostatin peptide, which is derived from IBIO-100. After the pre-clinical studies are completed, we will re-assess whether to further pursue the oncology program and have further discussions with the University of Pittsburgh. This approach allows us to gather valuable data and insights that will inform our future decisions regarding the potential of E4 endostatin peptide as an oncology program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, the Company purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 – Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon 3 key technologies. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Epitope Targeting Engine:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A patented machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subdominant and conformational epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than ”trial and error” antibody engineering and screening methods that are traditionally focused on dominant epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RubrYcHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combination of the Epitope Targeting Engine and screening with the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RubrYcHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Library has been shown to reduce the discovery time from ideation to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> proof-of-concept (PoC) by up to 4 months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic, faster. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">StableHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered sequence optimization library used to improve antibody performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Once an antibody has been advanced to the lead optimization stage, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">StableHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On January 3, 2023, the United States Patent and Trademark Office issued U.S. Patent No. 11,545,238, entitled “Machine Learning Method for Protein Modelling to Design Engineered Peptides,” which, among other claims, covers a machine learning model for engineering peptides, including antibody epitope therapeutics. Subject to any potential patent term extensions, the patent will expire on May 13, 2040.</p>
CY2022Q4	ibio	Cash And Cash Equivalents Plus Debt Securities CashAndCashEquivalentsPlusDebtSecurities	9900000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.60
CY2022Q4	us-gaap	Restructuring And Related Cost Expected Number Of Positions Eliminated RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated	69
CY2022Q4	ibio	Employee Reduction Expenses EmployeeReductionExpenses	1900000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent	800000
	ibio	Employee Reduction Expenses EmployeeReductionExpenses	33600000
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	17600000
	ibio	Disposal Group Including Discontinued Operation Inventory Write Down DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown	4900000
CY2022Q4	ibio	Disposal Group Including Discontinued Operation Personnel Costs Including Severance DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance	5800000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	130000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	168000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	22000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	113000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	108000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	55000
CY2022Q4	ibio	Discontinued Operations Research And Development Expenses DiscontinuedOperationsResearchAndDevelopmentExpenses	2462000
CY2021Q4	ibio	Discontinued Operations Research And Development Expenses DiscontinuedOperationsResearchAndDevelopmentExpenses	1472000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	1980000
CY2022Q4	ibio	Disposal Group Including Discontinued Operation Inventory Write Down DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown	833000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	2990000
CY2022Q4	ibio	Tangible Asset Impairment Charges Discontinued Operations TangibleAssetImpairmentChargesDiscontinuedOperations	17600000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	22875000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	4462000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	223000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	123000
CY2021Q4	ibio	Disposal Group Interest Expense Related Party DisposalGroupInterestExpenseRelatedParty	206000
CY2021Q4	ibio	Discontinued Operations Miscellaneous Expenses Income DiscontinuedOperationsMiscellaneousExpensesIncome	-7000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	223000
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	322000
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-22990000
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-4729000
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	186000
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	295000
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	27000
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	153000
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	159000
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	142000
	ibio	Discontinued Operations Research And Development Expenses DiscontinuedOperationsResearchAndDevelopmentExpenses	5524000
	ibio	Discontinued Operations Research And Development Expenses DiscontinuedOperationsResearchAndDevelopmentExpenses	2850000
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	5236000
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	5448000
	ibio	Tangible Asset Impairment Charges Discontinued Operations TangibleAssetImpairmentChargesDiscontinuedOperations	17600000
	ibio	Disposal Group Including Discontinued Operation Inventory Write Down DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown	4933000
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	33293000
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	8298000
	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	448000
	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	123000
	ibio	Disposal Group Interest Expense Related Party DisposalGroupInterestExpenseRelatedParty	814000
	ibio	Disposal Group Gain On Debt Forgiveness DisposalGroupGainOnDebtForgiveness	607000
	ibio	Discontinued Operations Miscellaneous Expenses Income DiscontinuedOperationsMiscellaneousExpensesIncome	1000
	ibio	Discontinued Operations Miscellaneous Expenses Income DiscontinuedOperationsMiscellaneousExpensesIncome	-6000
	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	449000
	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	324000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-33583000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-8480000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	25000
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	3900000
CY2022Q4	ibio	Disposal Group Operating Lease Right Of Use Assets DisposalGroupOperatingLeaseRightOfUseAssets	1947000
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Current DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent	18485000
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	20457000
CY2022Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	3900000
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent	35289000
CY2022Q2	ibio	Disposal Group Non Current Assets Finance Lease Right Of Use Assets DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets	74000
CY2022Q2	ibio	Disposal Group Operating Lease Right Of Use Assets Noncurrent DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent	1951000
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	37314000
CY2022Q2	ibio	Disposal Group Current Liabilities Finance Lease Obligations DisposalGroupCurrentLiabilitiesFinanceLeaseObligations	46000
CY2022Q4	ibio	Disposal Group Current Liabilities Operating Lease Obligations DisposalGroupCurrentLiabilitiesOperatingLeaseObligations	1947000
CY2022Q2	ibio	Disposal Group Current Liabilities Operating Lease Obligations DisposalGroupCurrentLiabilitiesOperatingLeaseObligations	10000
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1947000
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	56000
CY2022Q2	ibio	Disposal Group Noncurrent Liabilities Finance Lease Obligations DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations	30000
CY2022Q2	ibio	Disposal Group Noncurrent Operating Lease Obligations DisposalGroupNoncurrentOperatingLeaseObligations	1941000
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	1971000
	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	271000
	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	823000
	ibio	Disposal Group Amortization Of Finance Lease Right Of Use Assets DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets	20000
	ibio	Disposal Group Amortization Of Finance Lease Right Of Use Assets DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets	563000
	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	1070000
	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	25843000
	ibio	Tangible Asset Impairment Charges Discontinued Operations TangibleAssetImpairmentChargesDiscontinuedOperations	17600000
	ibio	Disposal Group Including Discontinued Operation Inventory Write Down DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown	4933000
	ibio	Disposal Group Fixed Assets Incurred But Not Yet Paid In Current Period DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod	1542000
	ibio	Disposal Group Fixed Assets Incurred But Not Yet Paid In Current Period DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod	791000
	ibio	Unpaid Fixed Assets Attributable To Discontinued Operations UnpaidFixedAssetsAttributableToDiscontinuedOperations	404000
CY2021Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	7500000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p>
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	426000
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0
CY2021Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0
CY2022Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	88000
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000
CY2021Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	423000
CY2022Q4	ibio	Percentage Of Collateral Required PercentageOfCollateralRequired	0.05
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	300000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6000000.0
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3696000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22676000
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	3949000
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	28672000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At December 31, 2022 and June 30, 2022, amounts in excess of insured limits were approximately $3,400,000 and $18,200,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended December 31, 2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the three months ended December 31, 2021, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from four customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the six months ended December 31, 2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from three customers. During the six months ended December 31, 2021, the Company reported revenue from continuing operations from one customer related to the settlement of a revenue contract and generated 100% of revenue reported in discontinued operations from four customers.</p>
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3400000
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	18200000
CY2021Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	7500000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	6067000
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11029000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	138000
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	184000
CY2022Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	5929000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	3667000
CY2022Q2	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	8054000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	2262000
CY2022Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	2791000
CY2022Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	5929000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	26000
CY2021Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	93000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	62000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	195000
CY2022Q4	ibio	Fixed Assets Held For Sale FixedAssetsHeldForSale	18485000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	68000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	746000
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	11383
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3603000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2873000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3068000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1967000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4360000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1373000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	115000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4245000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1373000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	115000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	115000
CY2022Q2	ibio	Fixed Assets Held For Sale FixedAssetsHeldForSale	35289000
	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	17600000
CY2023Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5946000
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	400000
	ibio	Impairment Of Intangible Assets Gross Of Reversals ImpairmentOfIntangibleAssetsGrossOfReversals	5946000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	400000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5270000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000
	ibio	Reversal Of Intangible Asset Impairment ReversalOfIntangibleAssetImpairment	5381000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	676000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	400000
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	565000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	395000
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4175000
	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	828000
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	5003000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4851000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5398000
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49000
CY2021Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	123000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	211000
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	565000
CY2022Q4	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	565000
CY2022Q4	ibio	Equipment Financing Amount Borrowed EquipmentFinancingAmountBorrowed	500000
CY2022Q4	ibio	Lessee Equipment Lease Term Of Contract LesseeEquipmentLeaseTermOfContract	P36M
CY2022Q4	ibio	Equipment Financing Lease Imputed Interest Rate EquipmentFinancingLeaseImputedInterestRate	0.1062
CY2022Q4	ibio	Equipment Leasing Monthly Installment Payable EquipmentLeasingMonthlyInstallmentPayable	16230
CY2022Q4	ibio	Equipment Financing Balance EquipmentFinancingBalance	474755
	ibio	Equipment Financing Interest Incurred EquipmentFinancingInterestIncurred	7200
CY2022Q4	ibio	Equipment Financing Interest Incurred EquipmentFinancingInterestIncurred	7200
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	319
CY2022Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	319
CY2022Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	213
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	851
CY2021Q2	ibio	Lessor Finance Lease Monthly Rent LessorFinanceLeaseMonthlyRent	3819
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	75000
CY2022Q4	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	16000
CY2022Q4	us-gaap	Lease Cost LeaseCost	91000
CY2022Q4	ibio	Financing Cash Flows From Finance Lease Obligation FinancingCashFlowsFromFinanceLeaseObligation	72000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	88000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	17000
	us-gaap	Lease Cost LeaseCost	105000
	ibio	Financing Cash Flows From Finance Lease Obligation FinancingCashFlowsFromFinanceLeaseObligation	82000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	746000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	259000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	490000
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M2D
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0950
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	195000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	194000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	163000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	552000
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	11383
CY2021Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P88M
CY2021Q3	ibio	Lessee Operating Lease Monthly Rent LesseeOperatingLeaseMonthlyRent	51223
CY2021Q3	ibio	Lessee Operating Lease Annual Percentage Increase In Base Rent LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent	0.03
CY2021Q3	us-gaap	Tenant Improvements TenantImprovements	81860
CY2022Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	140000
CY2021Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	177000
CY2022Q4	ibio	Total Operating Lease Costs TotalOperatingLeaseCosts	140000
CY2022Q4	ibio	Operating Cash Flows From Operating Lease Obligation OperatingCashFlowsFromOperatingLeaseObligation	48000
CY2021Q4	ibio	Operating Cash Flows From Operating Lease Obligation OperatingCashFlowsFromOperatingLeaseObligation	10000
CY2021Q4	ibio	Total Operating Lease Costs TotalOperatingLeaseCosts	177000
	us-gaap	Operating Lease Cost OperatingLeaseCost	281000
	us-gaap	Operating Lease Cost OperatingLeaseCost	212000
	ibio	Total Operating Lease Costs TotalOperatingLeaseCosts	281000
	ibio	Total Operating Lease Costs TotalOperatingLeaseCosts	212000
	ibio	Operating Cash Flows From Operating Lease Obligation OperatingCashFlowsFromOperatingLeaseObligation	51000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	315000
CY2022Q4	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year One LesseeOperatingLeaseImputedInterestToBePaidYearOne	255000
CY2022Q4	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year One LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne	570000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	412000
CY2022Q4	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Two LesseeOperatingLeaseImputedInterestToBePaidYearTwo	228000
CY2022Q4	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Two LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo	640000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	462000
CY2022Q4	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Three LesseeOperatingLeaseImputedInterestToBePaidYearThree	196000
CY2022Q4	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Three LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree	658000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	518000
CY2022Q4	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Four LesseeOperatingLeaseImputedInterestToBePaidYearFour	161000
CY2022Q4	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Four LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour	679000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	577000
CY2022Q4	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Five LesseeOperatingLeaseImputedInterestToBePaidYearFive	121000
CY2022Q4	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Five LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive	698000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1355000
CY2022Q4	ibio	Lessee Operating Lease Imputed Interest To Be Paid After Year Five LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive	106000
CY2022Q4	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid After Year Five LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive	1461000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3639000
CY2022Q4	ibio	Lessee Operating Lease Imputed Interest To Be Paid Total LesseeOperatingLeaseImputedInterestToBePaidTotal	1067000
CY2022Q4	ibio	Lessee Operating Lease Liability Principal And Imputed Interest LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest	4706000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	315000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3324000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2022Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10563000
CY2021Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7191000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-18100000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-12379000
CY2021Q4	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	22000
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	0
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	88000
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10563000
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-22990000
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7213000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18100000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12467000
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-4729000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-33583000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-8480000
CY2022Q4	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-33553000
CY2021Q4	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-11942000
	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-51683000
	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-20947000
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9807000
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8715000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9324000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8715000
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.08
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.83
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.94
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.43
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.34
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.54
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-3.60
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.97
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.42
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.40
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8933000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	681000
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	915000
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	960000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2041000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1680000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0321
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0361
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1552
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1693
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2022Q4	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	86000
CY2021Q4	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	29000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	190000
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	62000

Files In Submission

Name	View Source	Status
ibio-20221231_cal.xml	Edgar Link	unprocessable
ibio-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001420720-23-000009-index-headers.html	Edgar Link	pending
0001420720-23-000009-index.html	Edgar Link	pending
0001420720-23-000009.txt	Edgar Link	pending
0001420720-23-000009-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ibio-20221231.xsd	Edgar Link	pending
ibio-20221231x10q.htm	Edgar Link	pending
ibio-20221231x10q001.jpg	Edgar Link	pending
ibio-20221231x10q002.jpg	Edgar Link	pending
ibio-20221231xex10d2.htm	Edgar Link	pending
ibio-20221231xex10d3.htm	Edgar Link	pending
ibio-20221231xex10d3001.jpg	Edgar Link	pending
ibio-20221231xex10d4.htm	Edgar Link	pending
ibio-20221231xex10d4001.jpg	Edgar Link	pending
ibio-20221231xex31d1.htm	Edgar Link	pending
ibio-20221231xex31d2.htm	Edgar Link	pending
ibio-20221231xex32d1.htm	Edgar Link	pending
ibio-20221231xex32d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
ibio-20221231_lab.xml	Edgar Link	unprocessable
ibio-20221231_def.xml	Edgar Link	unprocessable
ibio-20221231x10q_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2023 Q1 Form 10-Q Financial Statement

#000142072023000009 Filed on February 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2023 Q1 Form 10-Q Financial Statement

#000142072023000009 Filed on February 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio